Renal histopathological lesions after orthotopic liver transplantation (OLT)

被引:118
作者
Pillebout, E [1 ]
Nochy, D
Hill, G
Conti, F
Antoine, C
Calmus, Y
Glotz, D
机构
[1] Hop St Louis, Paris, France
[2] Hop Europeen Georges Pomidou, Paris, France
[3] Hop Cochin, F-75674 Paris, France
关键词
interferon (IFN); liver transplantation; neoral FK506 nephrotoxicity; post-transplant diabetes; renal biopsy; renal failure;
D O I
10.1111/j.1600-6143.2005.00852.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Liver transplant recipients are at risk of chronic renal failure (CRF), customarily considered to be secondary to CsA/FK506 nephrotoxicity. We have examined renal biopsies from 26 liver transplant recipients with CRF. Before OLT, 5 patients had CRF, 8 were diabetic and 9 hypertensive. Renal biopsies were performed at a mean of 5 years after liver transplantation. Mean SCr was then 212 mu mol/L, proteinuria was 1 g/24 h. Twelve patients were diabetic and 25 hypertensive. Histology revealed impressive renal destruction, with a mean of 45% interstitial fibrosis and 45% glomerular sclerosis. All biopsies showed severe arteriosclerosis. CRF can be attributed to four associated primary lesions: (i) specific chronic CsA/FK506 arteriolopathy; (ii) typical diabetic nephropathy; (iii) acute or chronic thrombotic microangiopathy attributed to CsA/FK506 or alpha-IFN and (iv) tubular changes related to administration of hydroxyethylstarch. At the end of the follow-up, after a mean of 6.4 years, 12 patients required dialysis, 13 had CRF and only 1 had normal renal function. Thus, CRF in OLT recipients is more complex than originally thought and should not be classified as anti-calcineurin nephrotoxicity without further investigations, including renal histology. These investigations have therapeutic potential, that is, they may lead to a more aggressive treatment of hypertension and/or diabetes.
引用
收藏
页码:1120 / 1129
页数:10
相关论文
共 53 条
[1]  
Andoh TF, 1997, SEMIN NEPHROL, V17, P34
[2]   Renal thrombotic microangiopathy induced by interferon-α [J].
Badid, C ;
McGregor, B ;
Faivre, JM ;
Guerard, A ;
Juillard, L ;
Fouque, D ;
Laville, M .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 (04) :846-848
[3]   Hepatorenal syndrome [J].
Bataller, R ;
Ginès, P ;
Guevara, M ;
Arroyo, V .
SEMINARS IN LIVER DISEASE, 1997, 17 (03) :233-247
[4]   Chronic cyclosporine nephropathy: The Achilles' heel of immunosuppressive therapy [J].
Bennett, WM ;
DeMattos, A ;
Meyer, MM ;
Andoh, T ;
Barry, JM .
KIDNEY INTERNATIONAL, 1996, 50 (04) :1089-1100
[5]   Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection [J].
Caronia, S ;
Taylor, K ;
Pagliaro, L ;
Carr, C ;
Palazzo, U ;
Petrik, J ;
O'Rahilly, S ;
Shore, S ;
Tom, BDM ;
Alexander, GJM .
HEPATOLOGY, 1999, 30 (04) :1059-1063
[6]   Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients [J].
Cittanova, ML ;
Leblanc, I ;
Legendre, C ;
Mouquet, C ;
Riou, B ;
Coriat, P .
LANCET, 1996, 348 (9042) :1620-1622
[7]   Cutaneous thrombotic microangiopathy during treatment with Alpha-interferon for chronic hepatitis C [J].
Creput, C ;
Auffret, N ;
Samuel, D ;
Jian, R ;
Hill, G ;
Nochy, D .
JOURNAL OF HEPATOLOGY, 2002, 37 (06) :871-872
[8]   Nephrotoxicity of immunosuppressive drugs: Long-term consequences and challenges for the future [J].
de Mattos, AM ;
Olyaei, AJ ;
Bennett, WM .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 35 (02) :333-346
[9]  
Diabet Control Complications DCCT Res Grp, 1995, KIDNEY INT, V47, P1703
[10]  
DISTANT DA, 1993, J AM SOC NEPHROL, V4, P129